| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FILIP1L |
| Uniprot No | Q4L180 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-200aa |
| 氨基酸序列 | MVVDEQQRLTAQLTLQRQKIQELTTNAKETHTKLALAEARVQEEEQKATRLEKELQTQTTKFHQDQDTIMAKLTNEDSQNRQLQQKLAALSRQIDELEETNRSLRKAEEELQDIKEKISKGEYGNAGIMAEVEELRKRVLDMEGKDEELIKMEEQCRDLNKRLERETLQSKDFKLEVEKLSKRIMALEKLEDAFNKSKQE |
| 预测分子量 | 55.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FILIP1L重组蛋白的3篇代表性文献摘要信息：
1. **文献名称**：FILIP1L inhibits cell migration and invasion by regulating the PI3K/AKT signaling pathway in gastric cancer
**作者**：Chen Y, et al.
**摘要**：该研究通过重组FILIP1L蛋白实验，发现其通过抑制PI3K/AKT信号通路降低胃癌细胞侵袭转移能力，并验证了其对肿瘤转移的调控作用。
2. **文献名称**：Recombinant FILIP1L protein suppresses lung cancer progression via cytoskeleton remodeling
**作者**：Wang L, et al.
**摘要**：利用原核表达系统获得重组FILIP1L蛋白，发现其通过调控细胞骨架蛋白(如F-actin)重组抑制肺癌细胞迁移，并降低MMP-9表达水平。
3. **文献名称**：Functional characterization of FILIP1L in neuronal differentiation using recombinant protein delivery
**作者**：Suzuki K, et al.
**摘要**：通过重组FILIP1L蛋白递送至神经前体细胞，证实其促进神经元分化并抑制星形胶质细胞生成，提示其在神经发育疾病中的潜在治疗价值。
注：以上文献为示例性内容，实际文献需通过PubMed/Google Scholar等平台检索确认。建议使用关键词"FILIP1L recombinant"、"FILIP1L purification"等查找最新研究。
**Background of FILIP1L Recombinant Protein**
FILIP1L (Filamin A Interacting Protein 1-Like), also known as C18orf34 or CRMP1L, is a cytoskeletal regulatory protein implicated in diverse cellular processes, including cell motility, adhesion, and intracellular signaling. It interacts with filamin A (FLNA), a key actin-binding protein that stabilizes the cytoskeleton and mediates mechanotransduction. FILIP1L is structurally characterized by conserved domains that facilitate protein-protein interactions, particularly with FLNA, enabling modulation of actin filament organization and cell shape dynamics.
The gene encoding FILIP1L is located on chromosome 18 and is ubiquitously expressed, with higher levels observed in tissues like the brain, heart, and skeletal muscle. Studies suggest its involvement in pathological conditions, such as cancer metastasis, cardiovascular diseases, and neurological disorders. For instance, FILIP1L downregulation has been linked to enhanced tumor cell invasion by destabilizing FLNA-dependent cytoskeletal networks, while its overexpression may suppress metastatic potential.
Recombinant FILIP1L protein is engineered for in vitro and in vivo studies to dissect its molecular functions. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), it retains functional domains for binding partners like FLNA. Researchers utilize it to explore FILIP1L’s role in signaling pathways, such as TGF-β or integrin-mediated cascades, and to screen therapeutic agents targeting cytoskeletal dysregulation. Its application extends to developing diagnostic tools or biologics for diseases where cytoskeletal integrity is compromised.
Overall, FILIP1L recombinant protein serves as a critical tool for unraveling its biological significance and therapeutic potential in diseases driven by cytoskeletal aberrations.
×
